Extend two-field versus total two-field lymph node dissection for thoracic middle and lower esophageal squamous cell carcinoma: a prospective phase 2 study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100052277

Enrollment

Unknown

Registered

2021-10-24

Start date

2021-10-08

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer

Interventions

Group 1:Complete two-field lymph node dissection

Group 2:Extended two field lymph node dissection

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged >18 years and <=70 years. 2. Resectable esophageal squamous cell carcinoma in the middle or lower thoracic segment. 3. There is no metastatic lymph node in the mediastinum on preoperative clinical stage. 4. ECOG PS 0-1. 5. The main organs function normally. 6. No surgical contraindications. 7. The subjects have good compliance and cooperate with follow-up.

Exclusion criteria

Exclusion criteria: 1. Past history of malignant tumor; 2. The largest short diameter of the lymph nodes of the recurrent laryngeal nerve chain> 5mm.

Design outcomes

Primary

Measure	Time frame
Incidence of recurrent laryngeal nerve palsy within 30 days after operation;	—

Secondary

Measure	Time frame
Accuracy of lymph node staging by PET-CT;Complication rate within 30 days after operation;Incidence of pulmonary complications within 30 days after operation;2-year disease-free survival rate;2-year overall survival rate;	—

Countries

China

Contacts

Public ContactQin Jianjun

Chinese Academy of Medical Sciences Cancer Hospital

123114172@qq.com+86 18910758282

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026